- Home
- HEQ vs FATE Comparison
HEQ vs FATE Comparison
Compare HEQ & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEQ
- FATE
- Stock Information
- Founded
- HEQ 2011
- FATE 2007
- Country
- HEQ United States
- FATE United States
- Employees
- HEQ N/A
- FATE N/A
- Industry
- HEQ Investment Managers
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HEQ Finance
- FATE Health Care
- Exchange
- HEQ Nasdaq
- FATE Nasdaq
- Market Cap
- HEQ 128.4M
- FATE 116.5M
- IPO Year
- HEQ N/A
- FATE 2013
- Fundamental
- Price
- HEQ $10.63
- FATE $1.47
- Analyst Decision
- HEQ
- FATE Hold
- Analyst Count
- HEQ 0
- FATE 6
- Target Price
- HEQ N/A
- FATE $3.30
- AVG Volume (30 Days)
- HEQ 43.1K
- FATE 3.1M
- Earning Date
- HEQ 01-01-0001
- FATE 11-11-2025
- Dividend Yield
- HEQ 9.78%
- FATE N/A
- EPS Growth
- HEQ N/A
- FATE N/A
- EPS
- HEQ N/A
- FATE N/A
- Revenue
- HEQ N/A
- FATE $8,470,000.00
- Revenue This Year
- HEQ N/A
- FATE N/A
- Revenue Next Year
- HEQ N/A
- FATE N/A
- P/E Ratio
- HEQ N/A
- FATE N/A
- Revenue Growth
- HEQ N/A
- FATE N/A
- 52 Week Low
- HEQ $9.08
- FATE $0.66
- 52 Week High
- HEQ $11.84
- FATE $3.50
- Technical
- Relative Strength Index (RSI)
- HEQ 50.85
- FATE 62.81
- Support Level
- HEQ $10.46
- FATE $1.30
- Resistance Level
- HEQ $10.75
- FATE $1.65
- Average True Range (ATR)
- HEQ 0.13
- FATE 0.17
- MACD
- HEQ 0.01
- FATE 0.02
- Stochastic Oscillator
- HEQ 56.90
- FATE 73.77
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.